Variation in prescribing of lipid-lowering medication in primary care is associated with incidence of cardiovascular disease and all-cause mortality in people with screen-detected diabetes: Findings from the ADDITION-Denmark trial

Diabetic Medicine

Volumn 31, Issue 12, 2014, Pages 1577-1585

  Simmons, R K ^a   Carlsen, A H ^b   Griffin, S J ^a,c   Charles, M ^b   Christiansen, J S ^d   Borch Johnsen, K ^e   Sandbaek A ^b   Lauritzen, T ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e HOLBÆK HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; DENMARK; FEMALE; FOLLOW UP; GENERAL PRACTICE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; SENSITIVITY ANALYSIS; CARDIOVASCULAR DISEASES; CLINICAL PRACTICE; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; INCIDENCE; MASS SCREENING; MIDDLE AGED; PRIMARY HEALTH CARE; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; DENMARK; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; MORTALITY; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 84908687621     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12574     Document Type: Article

References (30)

1. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 1: CD004816.
2. National Institute of Health and Clinical Excellence (NICE). The Management of Type 2 Diabetes. London: NICE, 2008.
3. Thomsen RW, Johnsen SP, Olesen AV, Mortensen JT, Boggild H, Olsen J et al. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 2005; 60: 534-542.
4. Kedward J, Dakin L. A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care. Br J Gen Pract 2003; 53(494): 684-689.
5. Harnick DJ, Cohen JL, Schechter CB, Fuster V, Smith DA. Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease. Am J Cardiol 1998; 81: 1416-1420.
6. Baxter C, Jones R, Corr L. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. BMJ 1998; 317: 1134-1135.
7. Bradley CP. Factors which influence the decision whether or not to prescribe: the dilemma facing general practitioners. Br J Gen Pract 1992; 42: 454-458.
8. Lauritzen T, Sandbaek A, Carlsen AH, Borch-Johnsen K. All-cause mortality and pharmacological treatment intensity following a high risk screening program for diabetes. A 6.6 year follow-up of the ADDITION study, Denmark. Prim Care Diabetes 2012; 6: 193-200.
9. Murphy E, Kinmonth AL. No symptoms, no problem? Patients' understandings of non-insulin dependent diabetes. Fam Pract 1995; 12: 184-192.
10. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011; 378: 156-167.
11. Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 2004; 27: 727-733.
12. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622.
13. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
14. Royal College of General Practitioners in Denmark. Type 2-Diabetes in General Practice - Diagnosis and Treatment. Copenhagen: Royal College of General Practitioners, 1999.
15. UNESCO.International Standard Classification of Education. Montreal: UNESCO, 1997.
16. Organisation for Economic Co-operation and Development. What are Equivalence Scales?. Paris: OECD, 2008.
17. Kristensen JK, Bak JF, Wittrup I, Lauritzen T. Diabetes prevalence and quality of diabetes care among Lebanese or Turkish immigrants compared to a native Danish population. Prim Care Diabetes 2007; 1: 159-165.
18. Guldberg TL, Vedsted P, Kristensen JK, Lauritzen T. Improved quality of Type 2 diabetes care following electronic feedback of treatment status to general practitioners: a cluster randomized controlled trial. Diabet Med 2011; 28: 325-332.
19. Bennett KE, Williams D, Feely J. Under-prescribing of cardiovascular therapies for diabetes in primary care. Eur J Clin Pharmacol 2003; 58: 835-841.
20. Berthold HK, Gouni-Berthold I, Bohm M, Krone W, Bestehorn KP. Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovascular Diabetology 2009; 8: 25.
21. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000; 321: 1322-1325.
22. Thomsen TF, Jorgensen T, Ibsen H, Borch-Johnsen K. Assessment of coronary risk in general practice in relation to the use of guidelines: a survey in Denmark. Prev Med 2001; 33: 300-304.
23. Evans JS, Harries C, Dennis I, Dean J. General practitioners' tacit and stated policies in the prescription of lipid lowering agents. Br J Gen Pract 1995; 45: 15-18.
24. Korgsgaard P. Spilder millioner på helbredstjek. Mere gavn end skade. Eksperter advarer mod forebyggende helbredstjek, men det er de ligeglade med i landets kommuner. Ekstra Bladet 2013.
25. Olivarius NF. Ingen evidens for befolkningsbaseret screening for type 2-diabete (No evidence for population based screening for type 2 diabetes). Ugeskr Laeger 2012; 174: 2032.
26. Torjesen I. Government prioritises health checks for 15 million adults despite pre-election promise to scrap them. BMJ 2013; 346: f2941.
27. BMJ. Too much medicine. 2012. Available at: http://www.bmj.com/too-much-medicine.
28. Ravnskov U. Statins as the new aspirin. Conclusions from the heart protection study were premature. BMJ 2002; 324: 789.
29. Rubak S, Sandbaek A, Lauritzen T, Borch-Johnsen K, Christensen B. Effect of 'motivational interviewing' on quality of care measures in screen detected type 2 diabetes patients: a one-year follow-up of an RCT, ADDITION Denmark. Scand J Primary Health Care 2011; 29: 92-98.
30. Tiv M, Viel JF, Mauny F, Eschwege E, Weill A, Fournier C et al. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based study. PloS One 2012; 7: e32412.